OSLO, Norway, Dec. 4, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that new data from preclinical studies
investigating the effect of Betalutin® (177Lu-lilotomab
satetraxetan) on non-Hodgkin's lymphoma (NHL) cell lines will be
presented in a poster at the 61st American Society of
Hematology (ASH) Annual Meeting & Exposition (7-10 December 2019 in Orlando, FL, USA).
The ongoing research programme aims to investigate resistance
mechanisms that enable NHL cells to survive Betalutin® treatment
and to identify molecules that, when used in combination with
Betalutin®, could overcome that resistance. The findings of
this research could direct future programmes designed to expand the
use of Betalutin®-based therapies in NHL patients.
The research being presented at ASH builds on data previously
presented (at the European Haematology Association annual meeting
in June 2018) describing how a screen
of more than 50 different NHL cell lines identified some cell lines
that were resistant to Betalutin®. Two resistant cell lines were
aggressive diffuse large B-cell lymphoma (DLBCL) cell lines (the
double-hit/double-expressor ABC-DLBCL cell lines RIVA and
U2932).
The new poster reports how these two aggressive DLBCL cell lines
have been used in a new screen where Betalutin® has been combined
with 384 different anti-cancer drugs to identify the
Betalutin®/drug combinations that could potentially contribute to
reverting resistance.
Jostein Dahle, Chief Scientific
Officer of Nordic Nanovector, said: "Our ongoing research
programmes and collaborations continue to help us understand how
NHL cells react to Betalutin® treatment. Understanding the
mechanisms of resistance to Betalutin®, and how to overcome them,
is crucial for being able to deliver optimal treatment to patients
with difficult to treat tumours. In the case of Betalutin®-based
treatment, which to date has demonstrated an encouraging clinical
profile, such combination strategies could further enhance its
potential to become an important option for NHL
patients."
Abstract 2574
Abstract title: The Dual Cell Cycle Kinase Inhibitor
JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy
in Activated B Cell like Diffuse Large B Cell Lymphoma Cell
Lines
Authors: G.E. Rødland et al.
Session Name: 605. Molecular Pharmacology, Drug
Resistance-Lymphoid and Other Diseases: Poster II
Date: Sunday, 8 December
2019
Presentation Time: 6:00 PM - 8:00 PM
Eastern time
Location: Orange County Convention Center, Hall B
The abstract is available at
https://ash.confex.com/ash/2019/webprogram/Paper123287.html and the
poster will be published on the Nordic Nanovector website to
coincide with the session.
About ASH
The ASH annual meeting is the premier event for scientific
exchange in the field of haematology, attracting more than 20,000
attendees from all over the world. Typically, more than 5,000
scientific abstracts are submitted each year, and more than 3,000
abstracts are accepted for oral and poster presentations through an
extensive peer review process.
https://hematology.org/Annual-Meeting/
For further information, please contact:
IR enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication
with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets.
Further information can be found at
www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is subject to a duty of disclosure pursuant
to Sections 4-2 and 5-12 of the Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector--new-preclinical-data-offer-insights-into-enhancing-betalutin-based-therapies-in-n,c2981512